Status:
NOT_YET_RECRUITING
Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers
Lead Sponsor:
Huazhong University of Science and Technology
Collaborating Sponsors:
Wuhan Wuchang Hospital
Abinopharm, Inc
Conditions:
Sleep Disorder
Aging
Eligibility:
All Genders
45-70 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to evaluate the effects of Urolithin A (UA) and Fisetin on improving sleep and aging biomarkers in middle-aged and older adults. The main questions it aims to answer...
Detailed Description
The accelerating population aging has exacerbated the burden of chronic diseases among middle-aged and older adults, with sleep disorders emerging as a core health issue that forms a vicious cycle wit...
Eligibility Criteria
Inclusion
- Aged 45-70 years;
- Total score \> 5 points on the Pittsburgh Sleep Quality Index (PSQI) for sleep quality assessment;
- Able to use personal mobile devices for WeChat, internet access, and related operations;
- Informed about the intervention trial and willing to undergo sleep monitoring and other examinations during the study;
- Commitment to consume coffee, strong tea, or alcohol ≤1 time per week during the trial period;
Exclusion
- Participation in any clinical trials or dietary/exercise intervention programs within the past 3 months or concurrently;
- Diagnosis of major mental disorders or family history thereof, or current use of psychotropic drugs or mood-regulating medications;
- Experiencing major psychological trauma (e.g., death of a close relative, significant financial loss) personally or within the family in the past 3 months;
- Severe diseases affecting inflammatory levels and/or endocrine components (e.g., severe obesity, uncontrolled diabetes or poorly controlled blood glucose, myocardial infarction, cerebral infarction);
- Current use of hormonal medications, beta-blockers, steroids, non-steroidal anti-inflammatory drugs (NSAIDs), etc.;
- Use of medications potentially affecting sleep or aging biomarkers (e.g., melatonin, antidepressants, anxiolytics) within the past 3 months;
- Plans for relocation or long-term travel within the next 6 months, which may hinder continuous intervention and follow-up.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06990256
Start Date
September 1 2025
End Date
December 30 2026
Last Update
August 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wuchang Hospital Affiliated to Wuhan University of Science and Technology
Wuhan, Hubei, China, 430000